Effect of chronic antidepressant treatment on behavioural, neurochemical and endocrine changes following forced swim test exposure

1998 ◽  
Vol 8 ◽  
pp. S194 ◽  
Author(s):  
T.J. Connor ◽  
P. Kelliher ◽  
Y. Shen ◽  
A. Harkin ◽  
J.P. Kelly ◽  
...  
2017 ◽  
Vol 30 (3) ◽  
pp. 158-167 ◽  
Author(s):  
Patrick R. Suman ◽  
Nathalia Zerbinatti ◽  
Lais Cristina Theindl ◽  
Karolina Domingues ◽  
Cilene Lino de Oliveira

ObjectiveThe aims of this study were to replicate previously published experiments and to modify the protocol to detect the effects of chronic antidepressant treatment in mice.MethodsMale Swiss mice (n=6–8/group) housed in reversed light/dark cycle were randomly assigned into receive vehicle (10% sucrose), sub-effective doses (1 and 3 mg/kg) or effective doses (10 and 30 mg/kg) of bupropion, desipramine, and fluoxetine and a candidate antidepressant, sodium butyrate (1–30 mg/kg) per gavage (p.o.) 1 h before the forced swim test (FST). Treatments continued daily for 7 and 14 days during retests 1 and 2, respectively. In an additional experiment, mice received fluoxetine (20 mg/kg) or vehicle (10% sucrose or 0.9% saline) p.o. or i.p. before the FST. Mice housed in reversed or standard light/dark cycles received fluoxetine (20 mg/kg) prior FST. Video recordings of behavioural testing were used for blind assessment of the outcomes.ResultsAccording to the expected, doses of antidepressants considered sub-effective failed to affect the immobility time of mice in the FST. Surprisingly, acute and chronic treatment with the high doses of bupropion, desipramine, and fluoxetine or sodium butyrate also failed to reduce the immobility time of mice in the FST. Fluoxetine 20 mg/kg was also ineffective in the FST when injected i.p. or in mice housed in normal light/dark cycle.ConclusionData suggest the lack of efficacy of orally administered bupropion, desipramine, fluoxetine in the FST in Swiss mice. High variability, due to high and low immobility mice, may explain the limited effects of the treatments.


2011 ◽  
Vol 26 (S2) ◽  
pp. 802-802
Author(s):  
N. Kokras ◽  
C. Dalla ◽  
K. Antoniou ◽  
Z. Papadopoulou-Daifoti

IntroductionSex differences have been described in depression and more recently in antidepressant response. Animal models and in particular the Forced Swim Test (FST), are widely used to investigate the behavioural response to stress and to antidepressant treatment.ObjectivesThe present study explored sex differences in the stress response during the FST and examined whether antidepressant treatment alleviates the sex-differentiated stress response.MethodsAdult male and female Wistar rats were subjected to a 15 min FST session and then treated with three injections of sertraline 10 mg/kg or vehicle at 0, 19 and 23 hours post-FST. Twenty-four hours after the first FST, they had a second 5 min FST session and their behaviour was recorded.ResultsVehicle-treated females exhibited 66% longer duration and 70% shorter latency of immobility than males, suggesting enhanced levels of despair. Sertraline did not significantly affect immobility, but exerted its antidepressant effect by elongating swimming duration in both sexes and shortening climbing behaviour in males only. In contrast, to vehicle-treated rats, no sex differences were observed in sertraline-treated rats in any of these behavioural parameters. However, sex-differences in head swinging behaviour, which is unaffected by sertraline treatment, were still observed in sertraline-treated rats.ConclusionsFemales appear more vulnerable than males to the FST, but the post-treatment organisation of FST behaviour is not sex-differentiated. Antidepressants seem to modulate the behavioural response in FST in a sex-specific way, due to sex differences in baseline FST performance. Consequently, the sex-differentiated stress response profile during FST is attenuated by antidepressant treatment.


2008 ◽  
Vol 187 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Heidi Bächli ◽  
Michel A. Steiner ◽  
Ursula Habersetzer ◽  
Carsten T. Wotjak

2021 ◽  
pp. 01-09
Author(s):  
Mehnaz Gitay ◽  
Kausar Saboohi ◽  
Bushra Chaudhary ◽  
Samina Bano

Since the discovery that antidepressants work in part by potentiating the actions of 5-HT within the serotonergic system the effects these drugs elicit on the serotonin transporter (SERT) protein have been an area of active research. The aim of the present study is to understand the mechanism of action of tianeptine and sertraline in relation to its effects on the expression of SERT gene and SERT protein in the brain stem of stressed rats. Albino Wistar rats were divided into two groups (n=12) i.e. saline and drug. Each group was further divided into two equal groups, stressed (Forced Swim Test-FST) and unstressed. Tianeptine and sertraline were administered to rats orally for 4 weeks prior to subjecting them to forced swim test and decapitation. Tianeptine increased the expression of SERT gene though the protein is reduced in the brain stem in stress. On the contrary sertraline decreased the expression of SERT gene but increased the protein in the brain stem. The increase in swimming time in FST by both the drugs indicates stress alleviating effects. It can be concluded that Tianeptine prevents stress induced changes through its effect on the serotonergic system, including SERT mRNA and protein. Sertraline complies to the reuptake inhibition property by reducing SERT gene expression. Results are discussed specifically, how changes in SERT expression following chronic antidepressant treatment may contribute to the therapeutic benefits of antidepressants. Keywords: Antidepressants; Serotonin transporters; Stress; Serotonergic system; SERT gene expression


Author(s):  
Roni Yankelevitch-Yahav ◽  
Motty Franko ◽  
Avrham Huly ◽  
Ravid Doron

2021 ◽  
Vol 165 ◽  
pp. 56-57
Author(s):  
Shota Naoe ◽  
Takahiro Kataoka ◽  
Hina Shuto ◽  
Junki Yano ◽  
Tetsuya Nakada ◽  
...  

2019 ◽  
Vol 236 (11) ◽  
pp. 3353-3362 ◽  
Author(s):  
Mohammad Nasehi ◽  
Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani ◽  
Mohaddeseh Ebrahimi-Ghiri ◽  
Mohammad-Reza Zarrindast

2021 ◽  
pp. 1-7
Author(s):  
Dylan J. Terstege ◽  
Debra S. MacDonald ◽  
R. Andrew Tasker

Abstract Objective: Ginsenosides, biologically active components of the root of Panax ginseng, have been reported to have therapeutic benefits in a number of disease states including psychiatric conditions such as major depressive disorder. Our objective was to determine if a standardised commercial ginseng extract, G115®, could reduce the signs of behavioural despair commonly observed in animal models of depression either alone or in combination with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Methods: Male Sprague-Dawley (SD) rats (N = 51) were divided into four groups: vehicle control, G115® ginseng root extract, fluoxetine and fluoxetine plus G115®. Rats were trained to voluntarily consume treatments twice daily for 14 days and were then tested in an open field (OF), elevated plus maze (EPM) and forced swim test (FST). Post-mortem hippocampal and prefrontal cortex tissue was analysed for expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) by western blot. Results: One-way Analysis of Variance revealed no significant group differences in the OF or plus-maze performance on any variable examined. In the FST, fluoxetine significantly reduced immobility time and increased latency to immobility. The effects of fluoxetine were further significantly potentiated by co-administration of G115®. Post-mortem tissue analysis revealed significant group differences in BDNF expression in the left hippocampus and left prefrontal cortex without any accompanying changes in TrkB expression. Conclusions: We conclude that oral G115® significantly potentiates the antidepressant-like effect of fluoxetine in the FST in the absence of potentially confounding effects on locomotion and anxiety.


Sign in / Sign up

Export Citation Format

Share Document